Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caron A Jacobson

Showing results (71-80 of 140) with videos related to

Pageof 14
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaJennifer L Crombie, Austin I Kim, Robert Redd, et al.
Blood|June 9, 2022
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphomaPaola Ghione, M Lia Palomba, Anik R Patel, et al.
Blood Advances|November 15, 2024
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphomaAndrew Looka, David A Qualls, Daniel Matthews, et al.
British Journal of Cancer|December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphomaGeoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
British Journal of Haematology|August 16, 2023
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvementChristine E Ryan, Rebecca L Zon, Robert Redd, et al.
Transplantation and Cellular Therapy|August 26, 2024
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
Journal for Immunotherapy of Cancer|February 9, 2025
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registryDaniel J Landsburg, Matthew J Frigault, Michael Heim, et al.
Blood Advances|April 11, 2019
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemiaBenjamin L Lampson, Haesook T Kim, Matthew S Davids, et al.
The Lancet. Haematology|December 19, 2018
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b studyMatthew S Davids, Haesook T Kim, Alyssa Nicotra, et al.
The Lancet. Oncology|September 17, 2021
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, et al.
Pageof 14

Showing results (71-80 of 140) with videos related to

Sort By:
Pageof 14
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaJennifer L Crombie, Austin I Kim, Robert Redd, et al.
Blood|June 9, 2022
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphomaPaola Ghione, M Lia Palomba, Anik R Patel, et al.
Blood Advances|November 15, 2024
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphomaAndrew Looka, David A Qualls, Daniel Matthews, et al.
British Journal of Cancer|December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphomaGeoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
British Journal of Haematology|August 16, 2023
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvementChristine E Ryan, Rebecca L Zon, Robert Redd, et al.
Transplantation and Cellular Therapy|August 26, 2024
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
Journal for Immunotherapy of Cancer|February 9, 2025
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registryDaniel J Landsburg, Matthew J Frigault, Michael Heim, et al.
Blood Advances|April 11, 2019
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemiaBenjamin L Lampson, Haesook T Kim, Matthew S Davids, et al.
The Lancet. Haematology|December 19, 2018
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b studyMatthew S Davids, Haesook T Kim, Alyssa Nicotra, et al.
The Lancet. Oncology|September 17, 2021
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, et al.
Pageof 14